Reassessing therapeutic antibodies for neglected and tropical diseases

In the past two decades there has been a significant expansion in the number of new therapeutic monoclonal antibodies (mAbs) that are approved by regulators. The discovery of these new medicines has been driven primarily by new approaches in inflammatory diseases and oncology, especially in immuno-o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PLoS neglected tropical diseases 2020-01, Vol.14 (1), p.e0007860
Hauptverfasser:	Hooft van Huijsduijnen, Rob, Kojima, Somei, Carter, Dee, Okabe, Hisafumi, Sato, Akihide, Akahata, Wataru, Wells, Timothy N C, Katsuno, Kei
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies Antibodies, Monoclonal - pharmacology Biology and Life Sciences Cancer immunotherapy Costs Dengue Dengue - drug therapy Dengue fever Disease prophylaxis Drug Development Drug dosages FDA approval HIV Human diseases Human immunodeficiency virus Humans Immunization Immunization, Passive Infections Infectious diseases Inflammatory diseases Malaria Manufacturing industry Medicine and Health Sciences Mice Monoclonal antibodies Mycoses - drug therapy Neglected Diseases - drug therapy Oncology Peptides Poverty Prophylaxis Protection Proteins Regulators Research and Analysis Methods Respiratory syncytial virus Review Rheumatoid arthritis Schistosomiasis Schistosomiasis - drug therapy Success Tropical climate Tropical diseases Tropical Medicine Tumor necrosis factor-TNF Vector-borne diseases Viral diseases Viral infections Viroses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!